Serum Protein Fingerprinting by PEA Immunoassay Coupled with a Pattern-Recognition Algorithms Distinguishes MGUS and Multiple Myeloma

Total Page:16

File Type:pdf, Size:1020Kb

Serum Protein Fingerprinting by PEA Immunoassay Coupled with a Pattern-Recognition Algorithms Distinguishes MGUS and Multiple Myeloma www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 41), pp: 69408-69421 Research Paper Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma Petra Schneiderova1,*, Tomas Pika2,*, Petr Gajdos3, Regina Fillerova1, Pavel Kromer3, Milos Kudelka3, Jiri Minarik2, Tomas Papajik2, Vlastimil Scudla2 and Eva Kriegova1 1Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic 2Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic 3Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic *These authors have contributed equally to this work Correspondence to: Eva Kriegova, email: [email protected] Keywords: serum pattern, cytokines, growth factors, proximity extension immunoassay, post-transplant serum pattern Received: May 04, 2016 Accepted: July 28, 2016 Published: August 12, 2016 Copyright: Schneiderova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored. Using highly-sensitive Proximity Extension ImmunoAssay on 92 cancer biomarkers (Proseek Multiplex, Olink), enhanced serum levels of Adrenomedullin (ADM, Pcorr= .0004), Growth differentiation factor 15 (GDF15, Pcorr= .003), and soluble Major histocompatibility complex class I-related chain A (sMICA, Pcorr= .023), all prosurvival and chemoprotective factors for myeloma cells, were detected in MM comparing to MGUS. Comparison of MGUS and healthy subjects revealed elevation of angiogenic and antia-poptotic midkine (Pcorr= .0007) and downregulation of Transforming growth factor beta 1 (TGFB1, Pcorr= .005) in MGUS. Importantly, altered serum pattern was associated with MM-ASCT compared to paired MM at the diagnosis as well as to healthy controls, namely by upregulated B-Cell Activating Factor (sBAFF) (Pcorr< .006) and sustained elevation of other pro-tumorigenic factors. In conclusion, the serum fingerprints of MM and MM-ASCT were characteristic by elevated levels of prosurvival and chemoprotective factors for myeloma cells. INTRODUCTION with the best combination of currently available drugs, a cure is not achieved for most MM patients [2, 3]. Better Monoclonal gammopathy of undetermined characterization of neoplastic cells and microenvironment significance (MGUS) is a precursor lesion to overt in particular myeloma stages is therefore needed as well multiple myeloma (MM), a clonal B-cell malignancy as clarifying of reason(s) for treatment failure in most characterized by excessive multiplication of a plasma MM patients [2, 3, 4]. The neoplastic plasma cells in cell clone(s) in bone marrow, and accumulation of either MGUS and MM share similar genetic abnormalities, a monoclonal immunoglobulin (Ig) (M-protein) or an Ig- probably occurring as early events [5, 6]. The key role free light chain in blood [1]. During the last decade, MM in microenvironment play bone marrow stromal cells and treatment and patient outcomes improved remarkably other microenvironmental cells that secrete a plethora of after the introduction of novel agents and autologous cytokines and growth factors after paracrine stimulation stem cell transplantation (ASCT) [2]. However, even and/or direct interaction with neoplastic cells [7]. www.impactjournals.com/oncotarget 69408 Oncotarget Moreover, also myeloma cells secrete numerous cytokines based on cytogenetic/FISH analysis was not performed and growth factors [8, 9]. The secreted molecules may, in due to the high heterogeneity within the group. turn, promote homing, migration, proliferation, survival of malignant plasma cells as well as contribute to the bone Changes in serum protein pattern in resorption and drug resistance [10]. post-transplant MM Given the key role of cytokines and growth factors in MM pathogenesis, we investigated the complexity of To assess the changes in serum protein pattern serum microenvironment using novel multiplex highly- in MM after ASCT, we compared the post-transplant sensitive PEA immunoassay on 92 cancer-related proteins sera (day 100) with paired samples obtained in MM followed by pattern-recognition analyses. Besides patients at the time of diagnosis and healthy control identification of serum fingerprints distinguishing MGUS subjects. Comparing paired samples from MM- and MM, we for the first time compared paired MM ASCT and MM, the most upregulated protein in post- samples from the time of diagnosis and after autologous transplant sera was sBAFF (Pcorr= .006), followed by stem cell transplantation (MM-ASCT) as well as MGUS CXCL9 (Pcorr= .041). Next twenty-one proteins were to healthy subjects. downregulated (14 proteins after adjustment for multiple comparisons) in MM-ASCT comparing to MM (Figure RESULTS 2D, Supplementary Table S2D). The top-ranked proteins were: elevated sBAFF and downregulated REG4, Serum protein fingerprinting in MGUS and MM sPECAM1, sIL6R, sPDGFB, midkine, sHGF, TGFB1, by PEA immunoassay sAREG, and sMICA in MM-ASCT comparing to MM (Table 1D, Figure 3). Importantly, serum levels of MM- To assess the serum protein fingerprints associated associated pro-tumorigenic factors such as GDF15, with MGUS and MM, we compared serum protein CSF1, suPAR, and HE4 did not change after ASCT pattern obtained by PEA immunoassay in MGUS and comparing to sample at the diagnosis (Supplementary MM and healthy controls. Of ninety-two analyzed Table S2D). biomarkers (Supplementary Table S1), levels of six To exclude the influence of treatment regime biomarkers (sBTC, CA242, sER, GM-CSF, IL2, IL4) on serum pattern, we assessed the protein profile in were below the Proseek limit of detection (LOD) in all subgroups based on ASCT induction regime (IMiD-based/ studied groups and were therefore excluded from further bortezomib-based). We did not detect any differences in analysis. Comparing MGUS and MM, 26 analytes the cytokine levels as a function of the induction regime were deregulated between these groups, whereas 13 as well as the hematological response (CR, VGPR/PR) on analytes reached the significance after the adjustment day 100 (Pcorr> .05). for multiple comparisons (Supplementary Table S2A). Comparing to healthy subjects, the serum of The distribution of serum levels of top-ranked proteins post-transplant MM patients showed permanently (ADM, TRAP, GDF15, suPAR, REG4, TGFB1, sMICA, altered pro-tumorigenic signature characteristic by IL1RA, HE4, sHGFR, sVEGFA; see Table 1A), all found deregulation of 35 proteins (after multiple adjustments: upregulated in MM, is shown in Figure 1. The protein 28 analytes) (Figure 2E, Supplementary Table S2E). serum fingerprints associated with MGUS and MM and Except sTGFA and TGFB1, all deregulated proteins were the changes in protein levels between MGUS and MM for elevated in MM-ASCT. The top-ranked proteins between top-deregulated analytes are shown in Figure 2A. MM-ASCT and healthy controls were as follows: sBAFF, Comparison of protein pattern obtained in MGUS CSF1, sTGFA, TRAP, CXCL10, sTNFR2, sTNFRSF4, and healthy controls revealed deregulation of 33 Flt3L, GDF15, HE4, THPO (Table 1E, Supplementary proteins (Figure 2B), of these 21 reached significance Figure S1C). The serum protein pattern in MM-ASCT and after multiple comparisons (Supplementary Table S2B). its comparison to those of healthy controls, MGUS and The protein levels of top-ranked proteins (midkine, MM, are presented in Figure 4. THPO, sTNFRSF4, sHER4, INFγ, TGFB1, sPECAM1, sIL17RB, KLK6, suPAR) are presented in Table 1B and Pattern-recognition algorithms Supplementary Figure S1A. When comparing MM and controls, we observed To facilitate the selection of the most promising deregulation of 46 serum proteins (Figure 2C), of these 41 circulating proteins distinguishing studied groups analytes reached significance after adjustment for multiple (MGUS, MM, MM-ASCT, healthy subjects), we comparisons (Supplementary Table S2C). The distribution applied advanced binary classification algorithm and of serum levels of top-ranked proteins between MM and analyzed co-occurrence of analytes in classification controls (PGF, GDF15, HE4, sTNFR2, CSF1, midkine, models. The most accurate classification model for sPECAM1, CCL19, sVEGFA, INFγ; see Table 1C) is separation of MGUS and MM utilized in classification shown in Supplementary Figure S1B. The subanalysis rules most frequently sMICA in combination with other www.impactjournals.com/oncotarget 69409 Oncotarget Table 1: Serum levels of top-ranked proteins differentiating between A) MGUS vs MM, B) healthy controls vs MGUS, C) healthy controls vs MM, D) MM vs MM-ASCT and E) healthy controls vs MM-ASCT. Analyte Mean Linear ddCq (95% CI) FC P Pcorr A MGUS MM ADM 46.9 (28.4-65.4) 191 (121-262) 2.80 4.0 × 10-6 3.5 × 10-4 TRAP 28.9 (22.3-35.6) 85.1 (42.8-127) 2.33 3.7 × 10-5 1.6 × 10-3 GDF15 12.6 (9.19-16.0) 53.3 (22.5-84.1) 2.72 1.1 × 10-4 3.0 × 10-3 suPAR 295 (251-338) 486 (368-603) 1.60 2.7 × 10-4 5.9 × 10-3 REG4 5.96 (5.46-6.46) 9.58 (6.78-12.4) 1.30 1.2 × 10-3 .021 TGFB1 42.9 (39.0-46.8) 85.5 (43.7-127) 1.41
Recommended publications
  • Increased Expression of Epidermal Growth Factor Receptor and Betacellulin During the Early Stage of Gastric Ulcer Healing
    505-510 11/6/08 12:55 Page 505 MOLECULAR MEDICINE REPORTS 1: 505-510, 2008 505 Increased expression of epidermal growth factor receptor and betacellulin during the early stage of gastric ulcer healing GEUN HAE CHOI, HO SUNG PARK, KYUNG RYOUL KIM, HA NA CHOI, KYU YUN JANG, MYOUNG JA CHUNG, MYOUNG JAE KANG, DONG GEUN LEE and WOO SUNG MOON Department of Pathology, Institute for Medical Sciences, Chonbuk National University Medical School and the Center for Healthcare Technology Development, Jeonju, Korea Received January 2, 2008; Accepted February 22, 2008 Abstract. Epidermal growth factor receptor (EGFR) is from tissue necrosis triggered by mucosal ischemia, free important for the proliferation and differentiation of gastric radical formation and the cessation of nutrient delivery, which mucosal cells. Betacellulin (BTC) is a novel ligand for EGFR are caused by vascular and microvascular injury such as Since their role is unclear in the ulcer healing process, we thrombi, constriction or other occlusions (2). Tissue necrosis investigated their expression. Gastric ulcers in 30 Sprague- and the release of leukotriene B attract leukocytes and Dawley rats were induced by acetic acid. RT-PCR and macrophages, which release pro-inflammatory cytokines Western blotting were performed to detect EGFR and BTC. (e.g. TNFα, IL-1α, and IL-1ß). These in turn activate local Immunohistochemical studies were performed to detect fibroblasts, endothelial and epithelial cells. Histologically, an EGFR, BTC and proliferating cell nuclear antigen (PCNA). ulcer has two characteristic structures: a distinct ulcer margin The expression of EGFR and the BTC gene was significantly formed by the adjacent non-necrotic mucosa, and granulation increased at 12 h, 24 h and 3 days after ulcer induction tissue composed of fibroblasts, macrophages and proliferating (P<0.05).
    [Show full text]
  • Recombinant Human Betacellulin Promotes the Neogenesis of -Cells
    Recombinant Human Betacellulin Promotes the Neogenesis of ␤-Cells and Ameliorates Glucose Intolerance in Mice With Diabetes Induced by Selective Alloxan Perfusion Koji Yamamoto, Jun-ichiro Miyagawa, Masako Waguri, Reiko Sasada, Koichi Igarashi, Ming Li, Takao Nammo, Makoto Moriwaki, Akihisa Imagawa, Kazuya Yamagata, Hiromu Nakajima, Mitsuyoshi Namba, Yoshihiro Tochino, Toshiaki Hanafusa, and Yuji Matsuzawa Betacellulin (BTC), a member of the epidermal growth factor family, is expressed predominantly in the human pancreas and induces the differentiation of a pancreatic ancreatic ␤-cells are thought to be terminally dif- acinar cell line (AR42J) into insulin-secreting cells, ferentiated cells with little ability to regenerate. suggesting that BTC has a physiologically important However, proliferation of preexisting ␤-cells and role in the endocrine pancreas. In this study, we exam- differentiation of ␤-cells from precursor cells, ined the in vivo effect of recombinant human BTC P (rhBTC) on glucose intolerance and pancreatic mor- mainly residing in the pancreatic duct lining, have been phology using a new mouse model with glucose intoler- demonstrated in some animal models (1–5). Recently, we ance induced by selective alloxan perfusion. RhBTC developed a new mouse model of diabetes induced by selec- (1 µg/g body wt) or saline was injected subcutaneously tive perfusion of alloxan (100 µg/g body wt) during the every day from the day after alloxan treatment. The clamping of the superior mesenteric artery (1). In this model, intraperitoneal glucose tolerance test revealed no dif- glucose intolerance spontaneously resolves after one year ference between rhBTC-treated and rhBTC-untreated because of the proliferation of surviving ␤-cells in the non- glucose-intolerant mice at 2–4 weeks.
    [Show full text]
  • Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
    Review Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma John C. Chang 1,* and Madappa Kundranda 2 1 Division of Radiology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA 2 Division of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-480-256-3334 Academic Editor: Srikumar Chellappan Received: 23 January 2017; Accepted: 10 March 2017; Published: 20 March 2017 Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of reasons including very late diagnosis. This in part is due to the lack of understanding of the biological behavior of PDAC and the ineffective screening for this disease. Significant efforts have been dedicated to finding the appropriate serum and imaging biomarkers to help early detection and predict response to treatment of PDAC. Carbohydrate antigen 19-9 (CA 19-9) has been the most validated serum marker and has the highest positive predictive value as a stand-alone marker. When combined with carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA 125), CA 19-9 can help predict the outcome of patients to surgery and chemotherapy. A slew of novel serum markers including multimarker panels as well as genetic and epigenetic materials have potential for early detection of pancreatic cancer, although these remain to be validated in larger trials. Imaging studies may not correlate with elevated serum markers. Critical features for determining PDAC include the presence of a mass, dilated pancreatic duct, and a duct cut-off sign. Features that are indicative of early metastasis includes neurovascular bundle involvement, duodenal invasion, and greater post contrast enhancement.
    [Show full text]
  • POTENTIAL ROLE of MUC1 by Dahlia M. Besmer a Dissertatio
    THE DEVELOPMENT OF NOVEL THERAPEUTICS IN PANCREATIC AND BREAST CANCERS: POTENTIAL ROLE OF MUC1 by Dahlia M. Besmer A dissertation submitted to the faculty of The University of North Carolina at Charlotte in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology Charlotte 2013 Approved by: _____________________________ Dr. Pinku Mukherjee _____________________________ Dr. Valery Grdzelishvili _____________________________ Dr. Mark Clemens _____________________________ Dr. Didier Dréau _____________________________ Dr. Craig Ogle ii © 2013 Dahlia M. Besmer ALL RIGHTS RESERVED iii ABSTRACT DAHLIA MARIE BESMER. Development of novel therapeutics in pancreatic and breast cancers: potential role of MUC1. (Under the direction of DR. PINKU MUKHERJEE) Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer-related deaths in the US, and breast cancer (BC) contributes to ~40,000 deaths annually. The development of novel therapeutic agents for improving patient outcome is of paramount importance. Importantly, MUC1 is a mucin glycoprotein expressed on the apical surface of normal glandular epithelia but is over expressed and aberrantly glycosylated in >80% of human PDA and in >90% of BC. In the present study, we first utilize a model of PDA that is Muc1-null in order to elucidate the oncogenic role of MUC1. We show that lack of Muc1 significantly decreased proliferation, invasion, and mitotic rates both in vivo and in vitro. Next, we evaluated the anticancer efficacy of oncolytic virus (OV) therapy that utilizes viruses to kill tumor cells. The oncolytic potential of vesicular stomatitis virus (VSV) was analyzed in a panel of human PDA cell lines in vitro and in vivo in immune compromised mice.
    [Show full text]
  • Molecular and Clinical Markers of Pancreas Cancer
    JOP. J Pancreas (Online) 2010 Nov 9; 11(6):536-544. EDITORIAL Molecular and Clinical Markers of Pancreas Cancer James L Buxbaum1, Mohamad A Eloubeidi2 1Divisions of Gastroenterology and Hepatology, University of Southern California. Los Angeles, CA, USA. 2University of Alabama in Birmingham. Birmingham, AL, USA Summary Pancreas cancer has the worst prognosis of any solid tumor but is potentially treatable if it is diagnosed at an early stage. Thus there is critical interest in delineating clinical and molecular markers of incipient disease. The currently available biomarker, CA 19-9, has an inadequate sensitivity and specificity to achieve this objective. Diabetes mellitus, tobacco use, and chronic pancreatitis are associated with pancreas cancer. However, screening is currently only recommended in those with hereditary pancreatitis and genetic syndromes which predispose to cancer. Ongoing work to identify early markers of pancreas cancer consists of high throughput discovery methods including gene arrays and proteomics as well as hypothesis driven methods. While several promising candidates have been identified none has yet been convincingly proven to be better than CA 19-9. New methods including endoscopic ultrasound are improving detection of pancreas cancer and are being used to acquire tissue for biomarker discovery. Pancreas cancer has the darkest prognosis of any poor screening test. At the Samsung Medical Center in gastrointestinal cancer with the mortality approaching South Korea 70,940 asymptomatic patients were the incidence [1]. While the overall five year survival screened using CA 19-9. However, among 1,063 with is less than 4%, those recognized early, with tumor elevated levels only 4 had pancreas cancer and only 2 involving only the pancreas have a 25-30% five-year had resectable disease [6].
    [Show full text]
  • Human B-Cell Proliferation and Intracellular Signaling: Part 3
    1872 Diabetes Volume 64, June 2015 Andrew F. Stewart,1 Mehboob A. Hussain,2 Adolfo García-Ocaña,1 Rupangi C. Vasavada,1 Anil Bhushan,3 Ernesto Bernal-Mizrachi,4 and Rohit N. Kulkarni5 Human b-Cell Proliferation and Intracellular Signaling: Part 3 Diabetes 2015;64:1872–1885 | DOI: 10.2337/db14-1843 This is the third in a series of Perspectives on intracel- signaling pathways in rodent and human b-cells, with lular signaling pathways coupled to proliferation in pan- a specific focus on the links between b-cell proliferation creatic b-cells. We contrast the large knowledge base in and intracellular signaling pathways (1,2). We highlight rodent b-cells with the more limited human database. what is known in rodent b-cells and compare and contrast With the increasing incidence of type 1 diabetes and that to the current knowledge base in human b-cells. In- the recognition that type 2 diabetes is also due in part variably, the human b-cell section is very brief compared fi b to a de ciency of functioning -cells, there is great ur- with the rodent counterpart, reflecting the still primitive gency to identify therapeutic approaches to expand hu- state of our understanding of mitogenic signaling in hu- b man -cell numbers. Therapeutic approaches might man b-cells. To emphasize this difference, each figure is include stem cell differentiation, transdifferentiation, or divided into two panels, one summarizing rodent b-cell expansion of cadaver islets or residual endogenous signaling and one for human b-cells. Our intended audi- b-cells. In these Perspectives, we focus on b-cell ence includes trainees in b-cell regeneration as well as proliferation.
    [Show full text]
  • Blood Markers for Early Detection of Colorectal Cancer: a Systematic Review
    1935 Review Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review Sabrina Hundt, Ulrike Haug, and Hermann Brenner Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, Heidelberg, Germany Abstract Background: Despite different available methods for protein markers, but DNA markers and RNA colorectal cancer (CRC) screening and their proven markers were also investigated. Performance char- benefits, morbidity, and mortality of this malignancy are acteristics varied widely between different markers, still high, partly due to lowcompliance with screening. but also between different studies using the same Minimally invasive tests based on the analysis of blood marker. Promising results were reported for some specimens may overcome this problem. The purpose novel assays, e.g., assays based on SELDI-TOF MS of this reviewwas to give an overviewof published or MALDI-TOF MS, for some proteins (e.g., soluble studies on blood markers aimed at the early detection of CD26 and bone sialoprotein) and also for some CRC and to summarize their performance characteristics. genetic assays (e.g., L6 mRNA), but evidence thus Method: The PUBMED database was searched for far is restricted to single studies with limited relevant studies published until June 2006. Only studies sample size and without further external valida- with more than 20 cases and more than 20 controls were tion. included. Information on the markers under study, on Conclusions: Larger prospective studies using study the underlying study populations, and on performance populations representing a screening population are characteristics was extracted. Special attention was needed to verify promising results. In addition, future given to performance characteristics by tumor stage.
    [Show full text]
  • In Digestive Tract Diseases
    Br. J. Cancer 636-640 Macmillan Press Ltd., 1991 Br. J. Cancer (1991), 63, 636-640 ©%.J-'." Macmillan Press Ltd., Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases P. Kuusela', C. Haglund2 & P.J. Roberts2 'Department of Bacteriology and Immunology, University of Helsinki, Haartmaninkatu 3, SF-00290 Helsinki; and 2IV Department of Surgery, Helsinki University Central Hospital, Kasarminkatu 11-13, SF-00130 Helsinki, Finland. Summary The levels of CA 242, a new tumour marker of carbohydrate nature, were measured in sera of 185 patients with malignancies of the digestive tract and of 123 patients with benign digestive tract diseases. High percentages of elevated CA 242 levels (>20 U ml-') were recorded in patients with pancreatic and biliary cancers (68%). The sensitivity was somewhat lower than that of CA 19-9 (76%) and CA 50 (73%). On the other hand, in benign pancreactic and biliary tract diseases the CA 242 level was less frequently elevated than the CA 19-9 and CA 50 levels. The serum CA 242 concentration was increased in 55% of patients with colorectal cancer. CA 242 detected more Dukes A-B carcinomas (47%) than CEA (32%), whereas CEA was more often elevated (71% vs 59%) in Dukes C-D carcinomas. CA 242 was slightly elevated (ad 41 U ml-') in 10% of patients with benign colorectal diseases. CA 50 and CA 19-9 had lower sensitivities than CA 242 using the recommended cut-off values. When cut-off levels based on relevant benign colorectal diseases were used, the sensitivities of these markers were similar and somewhat higher than that of CEA.
    [Show full text]
  • Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Edited by Catharine M
    Laboratory Medicine Practice Guidelines Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Edited by Catharine M. Sturgeon and Eleftherios Diamandis NACB_LMPG_Ca1cover.indd 1 11/23/09 1:36:03 PM Tumor Markers.qxd 6/22/10 7:51 PM Page i The National Academy of Clinical Biochemistry Presents LABORATORY MEDICINE PRACTICE GUIDELINES USE OF TUMOR MARKERS IN TESTICULAR, PROSTATE, COLORECTAL, BREAST, AND OVARIAN CANCERS EDITED BY Catharine M. Sturgeon Eleftherios P. Diamandis Copyright © 2009 The American Association for Clinical Chemistry Tumor Markers.qxd 6/22/10 7:51 PM Page ii National Academy of Clinical Biochemistry Presents LABORATORY MEDICINE PRACTICE GUIDELINES USE OF TUMOR MARKERS IN TESTICULAR, PROSTATE, COLORECTAL, BREAST, AND OVARIAN CANCERS EDITED BY Catharine M. Sturgeon Eleftherios P. Diamandis Catharine M. Sturgeon Robert C. Bast, Jr Department of Clinical Biochemistry, Department of Experimental Therapeutics, University of Royal Infirmary of Edinburgh, Texas M. D. Anderson Cancer Center, Houston, TX Edinburgh, UK Barry Dowell Michael J. Duffy Abbott Laboratories, Abbott Park, IL Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Francisco J. Esteva Medicine and Medical Science, Conway Institute of Departments of Breast Medical Oncology, Molecular Biomolecular and Biomedical Research, University and Cellular Oncology, University of Texas M. D. College Dublin, Dublin, Ireland Anderson Cancer Center, Houston, TX Ulf-Håkan Stenman Caj Haglund Department of Clinical Chemistry, Helsinki University Department of Surgery, Helsinki University Central Central Hospital, Helsinki, Finland Hospital, Helsinki, Finland Hans Lilja Nadia Harbeck Departments of Clinical Laboratories, Urology, and Frauenklinik der Technischen Universität München, Medicine, Memorial Sloan-Kettering Cancer Center, Klinikum rechts der Isar, Munich, Germany New York, NY 10021 Daniel F.
    [Show full text]
  • Evaluation of Serum CEA, CA19-9, CA72-4, CA125 And
    www.nature.com/scientificreports OPEN Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Received: 20 October 2017 Accepted: 26 January 2018 Clinical Parameters for Colorectal Published: xx xx xxxx Cancer Yanfeng Gao1, Jinping Wang2, Yue Zhou3, Sen Sheng4, Steven Y. Qian5 & Xiongwei Huo6 Blood-based protein biomarkers have recently shown as simpler diagnostic modalities for colorectal cancer, while their association with clinical pathological characteristics is largely unknown. In this study, we not only examined the sensitivity and reliability of single/multiple serum markers for diagnosis, but also assessed their connection with pathological parameters from a total of 279 colorectal cancer patients. Our study shown that glycoprotein carcinoembryonic antigen (CEA) owns the highest sensitivity among single marker in the order of CEA > cancer antigen 72-4 (CA72-4) > cancer antigen 19-9 9 (CA19-9) > ferritin > cancer antigen 125 (CA125), while the most sensitive combined-markers for two to fve were: CEA + CA72-4; CEA + CA72-4 + CA125; CEA + CA19-9 + CA72-4 + CA125; and CEA + CA19-9 + CA72-4 + CA125 + ferritin, respectively. We also demonstrated that patients who had positive preoperative serum CEA, CA19-9, or CA72-4 were more likely with lymph node invasion, positive CA125 were prone to have vascular invasion, and positive CEA or CA125 were correlated with perineural invasion. In addition, positive CA19-9, CA72-4, or CA125 was associated with poorly diferentiated tumor, while CEA, CA19-9, CA72-4, CA125 levels were positively correlated with pathological tumor-node-metastasis stages. We here conclude that combined serum markers can be used to not only diagnose colorectal cancer, but also appraise the tumor status for guiding treatment, evaluation of curative efect, and prognosis of patients.
    [Show full text]
  • A Novel Multiplexed Immunoassay Identifies CEA, IL-8 and Prolactin As
    Mahboob et al. Clinical Proteomics (2015) 12:10 DOI 10.1186/s12014-015-9081-x CLINICAL PROTEOMICS RESEARCH Open Access A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers Sadia Mahboob1, Seong Beom Ahn1, Harish R Cheruku1, David Cantor1, Emma Rennel3, Simon Fredriksson3, Gabriella Edfeldt3, Edmond J Breen4, Alamgir Khan4, Abidali Mohamedali2, Md Golam Muktadir5, Shoba Ranganathan2, Sock-Hwee Tan1, Edouard Nice6 and Mark S Baker1* Abstract Background: Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes’ staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay.
    [Show full text]
  • CHBP Induces Stronger Immunosuppressive CD127+ M
    Li et al. Cell Death and Disease (2021) 12:177 https://doi.org/10.1038/s41419-021-03448-7 Cell Death & Disease ARTICLE Open Access CHBP induces stronger immunosuppressive CD127+ M-MDSC via erythropoietin receptor Jiawei Li1,2,GuoweiTu3, Weitao Zhang1,2,YiZhang2,4,XuepengZhang2,3,YueQiu2,3,JiyanWang2,5,TianleSun6, Tongyu Zhu1,2,7, Cheng Yang 1,2,8 and Ruiming Rong1,2,9 Abstract Erythropoietin (EPO) is not only an erythropoiesis hormone but also an immune-regulatory cytokine. The receptors of EPO (EPOR)2 and tissue-protective receptor (TPR), mediate EPO’s immune regulation. Our group firstly reported a non- erythropoietic peptide derivant of EPO, cyclic helix B peptide (CHBP), which could inhibit macrophages inflammation and dendritic cells (DCs) maturation. As a kind of innate immune regulatory cell, myeloid-derived suppressor cells (MDSCs) share a common myeloid progenitor with macrophages and DCs. In this study, we investigated the effects on MDSCs differentiation and immunosuppressive function via CHBP induction. CHBP promoted MDSCs differentiate toward M-MDSCs with enhanced immunosuppressive capability. Infusion of CHBP-induced M-MDSCs significantly prolonged murine skin allograft survival compared to its counterpart without CHBP stimulation. In addition, we found CHBP increased the proportion of CD11b+Ly6G−Ly6Chigh CD127+ M-MDSCs, which exerted a stronger immunosuppressive function compared to CD11b+Ly6G−Ly6Chigh CD127− M-MDSCs. In CHBP induced M-MDSCs, we found that EPOR downstream signal proteins Jak2 and STAT3 were upregulated, which had a strong relationship with MDSC function. In addition, CHBP upregulated GATA-binding protein 3 (GATA-3) protein translation level, which was an upstream signal of CD127 and regulator of STAT3.
    [Show full text]